The Oncomine Precision Assay features carefully curated biomarker content spanning 50 genes based on relevant evidence.
Enhanced fusion detection provides broad coverage for the most prevalent isoforms, along with novel fusions. You have the option to profile DNA or RNA from FFPE tissue or plasma, giving you a wide range of utility.
All of this is provided with one-day turnaround time and a highly automated workflow on the Genexus System.
Comprehensive genomic profiling (CGP) of cancer types is bringing crucial insights to the advancement of oncology research.
In the past, the ability to provide such complex data has been compromised by technology limitations such as high sample input requirements, sub-optimal sequencing success rates, as well as the nonexistence of streamlined end-to-end workflow which would enable laboratories to generate the required amounts of such data.
The Oncomine Comprehensive Assay offers robust performance and was chosen to participate in NCI MATCH, a large clinical oncology trial.
The Ion Torrent™ Oncomine™ BRCA Assay GX is a highly automated BRCA sequencing solution deployed on the Ion Torrent™ Genexus™ System.
Labs can detect BRCA somatic and germline mutations including large genomic rearrangement, such as large insertions and deletions (indels) and exon-level duplication and deletion, without the need to employ multiple technologies, in a specimen-to-report workflow that delivers results in as little as one day.
Hematological disorders are complex, heterogeneous diseases with many oncogenic drivers and subtypes. Acute forms of hematological malignancies are very aggressive and can proliferate rapidly.
Getting fast, accurate, and meaningful insights is essential in helping to advance our understanding of these disorders. Whether you're interested in the assessment of myeloid or lymphoid malignancy
samples, we provide the comprehensive suite of tools you need lo simplify and expedite your path to answers.
> Explore our growing portfolio of Oncomine hemato-oncology research assays.
1-day genomic profiling for myeloid malignancy research
With the Ion Torrent Oncomine Myeloid Assay Gx on the Ion Torrent Genexus System, you can get a comprehensive myeloid mutational profile from a single next-generation sequencing (NGS) run and results in just one day. A highly integrated workflow lets you go from specimen to report with only 10 minutes of hands-on time and two user touch points*. It’s never been easier to implement myeloid NGS testing in your lab.
> Explore Oncomine Myeloid Assay GX
The Ion Torrent Oncomine Myeloid MRD Assays (RUO) on the Ion GeneStudio S5 System is a complete NGS testing solution for myeloid measurable residual disease (MRD) research.
Highly sensitive AmpliSeq HD technology enables a limit of detection as low as 0.05% allele frequency.
Unlike traditional methods, NGS allows you to obtain informative data across a broad range of biomarkers simultaneously. A DNA and an RNA assay enable comprehensive assessment of genetic alterations, including SNVs, indels, and gene fusions.
Oncomine immune repertoire assays target B-cell and T-cell receptor chains with extremely high sensitivity and specificity for clonality assessment, rare clone detection, and somatic hypermutation analysis of lymphoid neoplasm samples.
> Explore Immune Repertoire Assays
End-to-end solutions for liquid biopsy cancer research.
Whether you’re looking at multiple targets or just a few, our NGS solutions combine the power of Ion Torrent technology with cfDNA assays, advanced rare cell isolation, manual or automated cell-free DNA extraction, and digital PCR tools. Together, these solutions enable you to retrospectively assess cancer research samples throughout all stages.
> Explore Liquid Biopsy Assays
Tumor Mutation Burden and other standard biomarkers from a single sample.
Tumor mutation burden (TMB) is an emerging biomarker that is rapidly gaining traction within the immuno-oncology field. Recent clinical trials have demonstrated that patients with higher TMB are more likely to respond to checkpoint inhibitor therapies, so it will likely become a part of routine clinical biomarker testing in the near future.
Studies have shown that NGS is the best technique for detecting TMB. The Oncomine Tumor Mutation Load Assay is one of the only NGS solution available for use in clinical research laboratories that delivers a TMB assessment in one test workflow with other biomarkers.
Watch a short video of key opinion leaders talking about their experience with the test and assessing tumor mutation burden in ~2.5 days.
